Yoon-Koo Kang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7555903/publications.pdf

Version: 2024-02-01

393 papers	38,695 citations	10956 71 h-index	3173 186 g-index
398 all docs	398 docs citations	398 times ranked	29120 citing authors

#	Article	IF	Citations
1	Prognostic value of natural killer cell activity for patients with HER2â€‰+â€‰advanced gastric cancer treated with first-line fluoropyrimidineâ€“platinum doublet plus trastuzumab. Cancer Immunology, Immunotherapy, 2022, 71, 829-838.	2.0	7
2	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer, 2022, 25, 207-217.	2.7	9
3	Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study. Gastric Cancer, 2022, 25, 170-179.	2.7	6
4	Insertionâ€“deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab. Gastric Cancer, 2022, 25, 226-234.	2.7	8
5	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2022, 23, 234-247.	5.1	268
6	Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): Systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC).. Journal of Clinical Oncology, 2022, 40, 344-344.	0.8	4
7	Predictive biomarkers for the efficacy of nivolumab asâ€‰â‰¥â€‰3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer, 2022, 22, 378.	1.1	16
8	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
9	Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis. Cancer Research and Treatment, 2022, 54, 1167-1174.	1.3	8
10	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTEâ€063): A randomized, openâ€label, phase 3 trial in Asian patients. Cancer, 2022, 128, 995-1003.	2.0	27
11	Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer, 2022, 25, 794-803.	2.7	7
12	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	17
13	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
14	Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer. Cancer Research, 2022, 82, CT015-CT015.	0.4	2
15	Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2022, 40, 101-101.	0.8	3
16	Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.. Journal of Clinical Oncology, 2022, 40, 11539-11539.	0.8	0
17	First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, 2501-2501.	0.8	7
18	Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.. Journal of Clinical Oncology, 2022, 40, 11541-11541.	0.8	2

#	Article	IF	Citations
19	A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.. Journal of Clinical Oncology, 2022, 40, 11538-11538.	0.8	0
20	Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).. Journal of Clinical Oncology, 2022, 40, TPS4165-TPS4165.	0.8	6
21	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 4032-4032.	0.8	6
22	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer, 2021, 24, 156-167.	2.7	29
23	MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncology, 2021, 17, 1155-1164.	1.1	64
24	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Reports, 2021, 3, 100215.	2.6	31
25	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist, 2021, 26, e622-e631.	1.9	20
26	Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2021, 39, TPS264-TPS264.	0.8	4
27	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist, 2021, 26, e639-e649.	1.9	29
28	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 2021, 124, 1388-1397.	2.9	39
29	Gastrointestinal stromal tumours. Nature Reviews Disease Primers, 2021, 7, 22.	18.1	169
30	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer, 2021, 145, 132-142.	1.3	75
31	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958.	2.7	61
32	Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2â€“Targeted Agent in the Real-World Setting. Cancer Research and Treatment, 2021, 53, 436-444.	1.3	4
33	Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. Journal of Clinical Oncology, 2021, 39, TPS2656-TPS2656.	0.8	4
34	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).. Journal of Clinical Oncology, 2021, 39, 4010-4010.	0.8	27
35	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. Journal of Clinical Oncology, 2021, 39, 2903-2913.	0.8	154
36	Reply to D.-C. Mo et al. Journal of Clinical Oncology, 2021, 39, 3884-3886.	0.8	1

#	Article	IF	Citations
37	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
38	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of Clinical Oncology, 2021, 39, 3128-3139.	0.8	56
39	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).. Journal of Clinical Oncology, 2021, 39, 160-160.	0.8	64
40	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. Journal of Clinical Oncology, 2021, 39, 164-164.	0.8	21
41	402â€…Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer. , 2021, 9, A433-A433.		0
42	New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. World Journal of Gastroenterology, 2021, 27, 8357-8369.	1.4	0
43	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 143-153.	2.7	45
44	Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor. Investigational New Drugs, 2020, 38, 493-499.	1.2	4
45	Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 135-144.	2.9	39
46	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 2020, 23, 510-519.	2.7	155
47	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. JAMA Oncology, 2020, 6, e204564.	3.4	746
48	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1045-1056.	5.1	39
49	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer, 2020, 9, 440-454.	4.2	10
50	Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. Oncologist, 2020, 25, e1785-e1793.	1.9	4
51	The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene. Biochemical and Biophysical Research Communications, 2020, 529, 699-706.	1.0	9
52	Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040. Journal of Hepatology, 2020, 73, S121-S122.	1.8	3
53	Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success. Scientific Reports, 2020, 10, 7996.	1.6	4
54	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80

#	Article	IF	Citations
55	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2020, 21, 935-946.	5.1	186
56	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. Lancet Oncology, The, 2020, 21, 1066-1076.	5.1	130
57	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1630-1637.	2.9	472
58	Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Antiâ€“c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2020, 19, 1210-1217.	1.9	17
59	Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFÎ² and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clinical Cancer Research, 2020, 26, 3202-3210.	3.2	24
60	401â€¦Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , .		2
61	Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3063-3063.	0.8	8
62	Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology, 2020, 38, 4508-4508.	0.8	86
63	Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1â€“positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.. Journal of Clinical Oncology, 2020, 38, e16586-e16586.	0.8	3
64	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. Journal of Clinical Oncology, 2020, 38, TPS3145-TPS3145.	0.8	6
65	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.. Journal of Clinical Oncology, 2020, 38, 383-383.	0.8	10
66	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.. Journal of Clinical Oncology, 2020, 38, 512-512.	0.8	31
67	Clinical activity of avapritinib in â‰¥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2020, 38, 826-826.	0.8	5
68	Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).. Journal of Clinical Oncology, 2020, 38, TPS468-TPS468.	0.8	2
69	Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 621-630.	0.7	7
70	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3054-3054.	0.8	1
71	Prognostic role of mismatch repair deficiency (MMR-D) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy for metastatic and locally advanced unresectable gastric cancers (GCs).. Journal of Clinical Oncology, 2020, 38, 4566-4566.	0.8	1
72	Diagnostic accuracy of CT-staging of advanced gastric cancer following neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2020, 38, 4551-4551.	0.8	0

#	Article	IF	Citations
73	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. JAMA Network Open, 2019, 2, e198243.	2.8	25
74	Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. Oncologist, 2019, 24, e1443-e1449.	1.9	4
75	Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1686-1695.	7.7	75
76	Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours. British Journal of Cancer, 2019, 121, 819-826.	2.9	2
77	Longâ€term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14â€year, singleâ€center experience. Cancer Medicine, 2019, 8, 1034-1043.	1.3	11
78	Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer, 2019, 22, 803-816.	2.7	36
79	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 282-296.	5.1	1,202
80	Neoadjuvant Treatment for Gastric Cancer. , 2019, , 343-352.		0
81	Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. Journal of Hepatology, 2019, 71, 543-552.	1.8	180
82	EORTC-1203-GITCG - the â€œINNOVATIONâ€•trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 2019, 19, 494.	1.1	86
83	Pharmacokinetic and exposureâ€“response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 539-550.	1.1	7
84	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer, 2019, 22, 828-837.	2.7	181
85	Perioperative FLOT: new standard for gastric cancer?. Lancet, The, 2019, 393, 1914-1916.	6.3	11
86	Avelumab (antiâ€“PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
87	Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. Oncologist, 2019, 24, e1212-e1218.	1.9	12
88	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1696-1707.	7.7	157
89	Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Annals of Oncology, 2019, 30, 250-258.	0.6	230
90	A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors. Clinical Cancer Research, 2019, 25, 2414-2423.	3.2	54

#	Article	IF	Citations
91	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer, 2019, 22, 527-535.	2.7	88
92	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer, 2019, 22, 344-354.	2.7	60
93	Clinical activity of avapritinib in â‰¥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2019, 37, 11022-11022.	0.8	17
94	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. Journal of Clinical Oncology, 2019, 37, 4012-4012.	0.8	178
95	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH,) Tj ETQq1 1 0.784314 rgBT /Ove		
96	Predictive biomarkers for the efficacy of nivolumab as â‰¥ third-line therapy in patients with advanced gastric cancer (AGC): From a subset analysis of ATTRACTION-2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 152-152.	0.8	6
97	Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline Î±-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.. Journal of Clinical Oncology, 2019, 37, 326-326.	0.8	8
98	Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).. Journal of Clinical Oncology, 2019, 37, 65-65.	0.8	15
99	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. Journal of Clinical Oncology, 2019, 37, 8-8.	0.8	3
100	Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 620-631.	0.7	4
101	Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors â€”8 cases: A case report. World Journal of Gastroenterology, 2019, 25, 2010-2018.	1.4	3
102	Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer, 2018, 21, 802-810.	2.7	7
103	Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Annals of Oncology, 2018, 29, 1220-1226.	0.6	36
104	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer, 2018, 21, 819-830.	2.7	24
105	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. British Journal of Cancer, 2018, 118, 938-946.	2.9	29
106	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. Gastric Cancer, 2018, 21, 429-438.	2.7	26
107	Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncology, The, 2018, 19, 1372-1384.	5.1	319
108	Prognostic impact of extranodal extension in stage 1B gastric carcinomas. Surgical Oncology, 2018, 27, 299-305.	0.8	7

#	Article	IF	Citations
109	Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors. Korean Journal of Radiology, 2018, 19, 54.	1.5	17
110	Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study. Liver Cancer, 2018, 7, 148-164.	4.2	12
111	Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).. Journal of Clinical Oncology, 2018, 36, 2564-2564.	0.8	1
112	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. Journal of Clinical Oncology, 2018, 36, 4003-4003.	0.8	77
113	Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. Journal of Clinical Oncology, 2018, 36, 4030-4030.	0.8	9
114	Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).. Journal of Clinical Oncology, 2018, 36, 4036-4036.	0.8	6
115	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-Î², in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial.. Journal of Clinical Oncology, 2018, 36, 100-100.	0.8	7
116	Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).. Journal of Clinical Oncology, 2018, 36, 140-140.	0.8	13
117	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. Journal of Clinical Oncology, 2018, 36, 475-475.	0.8	39
118	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, 90-90.	0.8	1
119	Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).. Journal of Clinical Oncology, 2018, 36, 92-92.	0.8	20
120	Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Research and Treatment, 2018, 50, 518-529.	1.3	10
121	Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses.. Journal of Clinical Oncology, 2018, 36, 11532-11532.	0.8	1
122	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, e15127-e15127.	0.8	0
123	Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.. Journal of Clinical Oncology, 2018, 36, 11537-11537.	0.8	0
124	Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. Gastric Cancer, 2017, 20, 146-155.	2.7	11
125	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIBâ€“IV gastric cancer. Gastric Cancer, 2017, 20, 182-189.	2.7	6
126	Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 167-174.	0.6	5

#	Article	IF	Citations
127	Unmet needs of nonâ€Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with healthâ€related quality of life. Psycho-Oncology, 2017, 26, 330-336.	1.0	16
128	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 2017, 66, 1166-1172.	1.8	178
129	A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. Oncologist, 2017, 22, 129-e8.	1.9	18
130	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	6.3	3,224
131	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Targeted Oncology, 2017, 12, 463-474.	1.7	64
132	Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. British Journal of Cancer, 2017, 117, 25-32.	2.9	74
133	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncology, The, 2017, 18, 640-653.	5.1	383
134	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis. Gastric Cancer, 2017, 20, 970-977.	2.7	13
135	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 180-188.	1.2	647
136	A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas. Pathology, 2017, 49, 38-43.	0.3	13
137	Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemotherapy and Pharmacology, 2017, 79, 139-146.	1.1	28
138	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1197-1207.	1.1	27
139	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	6.3	1,749
140	Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. Annals of Oncology, 2017, 28, iii139.	0.6	2
141	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Research and Treatment, 2017, 49, 851-868.	1.3	50
142	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0172307.	1.1	11
143	Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PLoS ONE, 2017, 12, e0176045.	1.1	28
144	Prognostic impact offibroblast growth factor receptor 2gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers. Oncotarget, 2017, 8, 33844-33854.	0.8	20

#	Article	IF	Citations
145	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 4013-4013.	0.8	76
146	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. Journal of Clinical Oncology, 2017, 35, 4073-4073.	0.8	133
147	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. Journal of Clinical Oncology, 2017, 35, 2-2.	0.8	64
148	Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).. Journal of Clinical Oncology, 2017, 35, 27-27.	0.8	4
149	Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. Oncotarget, 2017, 8, 76712-76721.	0.8	5
150	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Cancer Research and Treatment, 2017, 49, 350-357.	1.3	23
151	Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study. World Journal of Gastrointestinal Oncology, 2017, 9, 176.	0.8	14
152	Serial monitoring of imatinib pharmacokinetics (PK) in perioperative imatinib treatment in patients (pts) with gastrointestinal stromal tumors (GISTs): Results from the multinational phase II trial.. Journal of Clinical Oncology, 2017, 35, 118-118.	0.8	0
153	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget, 2016, 7, 10547-10556.	0.8	52
154	Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. Gastroenterology Research and Practice, 2016, 2016, 1-6.	0.7	4
155	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Research and Treatment, 2016, 48, 1155-1166.	1.3	142
156	Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib. International Journal of Dermatology, 2016, 55, e268-74.	0.5	10
157	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 2016, 22, 4870-4879.	3.2	26
158	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 296-304.	1.8	26
159	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clinical Cancer Research, 2016, 22, 6228-6235.	3.2	40
160	A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. Oncologist, 2016, 21, 1085-1090.	1.9	82
161	Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer, 2016, 16, 900.	1.1	67
162	Gastric Cancer Management â€" East vs. West?. , 2016, , 133-152.		0

#	Article	IF	Citations
163	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 2728-2735.	0.8	183
164	Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. British Journal of Cancer, 2016, 114, 1185-1190.	2.9	35
165	Randomized, openâ€label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology, 2016, 64, 774-784.	3.6	77
166	Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer, 2016, 19, 226-233.	2.7	32
167	Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). European Journal of Cancer, 2016, 53, 42-50.	1.3	76
168	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer, 2016, 16, 22.	1.1	52
169	Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). European Journal of Cancer, 2016, 52, 201-208.	1.3	8
170	Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. Gastric Cancer, 2016, 19, 579-585.	2.7	11
171	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer, 2016, 19, 3-14.	2.7	339
172	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. Journal of Clinical Oncology, 2016, 34, 2508-2508.	0.8	21
173	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 4009-4009.	0.8	42
174	Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study.. Journal of Clinical Oncology, 2016, 34, 4015-4015.	0.8	12
175	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. Journal of Clinical Oncology, 2016, 34, 4016-4016.	0.8	3
176	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. Journal of Clinical Oncology, 2016, 34, 4078-4078.	0.8	30
177	First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS2597-TPS2597.	0.8	4
178	Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, TPS3103-TPS3103.	0.8	5
179	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancerâ€"INNOVATION trial.. Journal of Clinical Oncology, 2016, 34, TPS4133-TPS4133.	0.8	2
180	Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2016, 34, 156-156.	0.8	9

#	Article	IF	Citations
181	Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. Journal of Clinical Oncology, 2016, 34, 167-167.	0.8	27
182	A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).. Journal of Clinical Oncology, 2016, 34, 5-5.	0.8	54
183	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€"A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2016, 34, 64-64.	0.8	3
184	Clinical significance of MET amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum (FP) combination chemotherapy.. Journal of Clinical Oncology, 2016, 34, 69-69.	0.8	1
185	Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. Oncotarget, 2016, 7, 74303-74313.	0.8	19
186	Current Status and Challenges of Cancer Clinical Trials in Korea. Cancer Research and Treatment, 2016, 48, 20-27.	1.3	9
187	Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alphaâ€"Mutated Gastrointestinal Stromal Tumors. Cancer Research and Treatment, 2016, 48, 546-552.	1.3	38
188	Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Research and Treatment, 2016, 48, 162-170.	1.3	13
189	A multinational phase II clinical trial of neoadjuvant imatinib for large gastrointestinal stromal tumor of the stomach.. Journal of Clinical Oncology, 2016, 34, 130-130.	0.8	1
190	Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 329-329.	0.8	15
191	Perioperative treatments for resectable gastric cancer. Journal of the Korean Medical Association, 2015, 58, 201.	0.1	3
192	FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. American Journal of Clinical Pathology, 2015, 143, 865-872.	0.4	18
193	Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Annals of Oncology, 2015, 26, 2097-2101.	0.6	41
194	Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial. Clinical Investigation, 2015, 5, 665-675.	0.0	1
195	Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Annals of Oncology, 2015, 26, 2457-2463.	0.6	85
196	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 2015, 26, 320-329.e6.	0.2	75
197	Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatmentâ€use trial of sunitinib. Cancer, 2015, 121, 1405-1413.	2.0	89
198	Intraoperatively Assessed Macroscopic Serosal Changes in Patients with Curatively Resected Advanced Gastric Cancer: Clinical Implications for Prognosis and Peritoneal Recurrence. Annals of Surgical Oncology, 2015, 22, 2940-2947.	0.7	14

#	Article	IF	Citations
199	Predicting the Efficacy of an Oral Paclitaxel Formulation (DHP107) Through Modeling and Simulation. Clinical Therapeutics, 2015, 37, 402-417.	1.1	13
200	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2015, 75, 173-182.	1.1	37
201	A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA). Cancer Chemotherapy and Pharmacology, 2015, 75, 309-318.	1.1	4
202	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. Journal of Hepatology, 2015, 63, 896-904.	1.8	44
203	Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. European Journal of Cancer, 2015, 51, 482-488.	1.3	103
204	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 550-560.	5.1	96
205	Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression. BMC Cancer, 2015, 15, 119.	1.1	23
206	Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. Annals of Surgical Oncology, 2015, 22, 362-369.	0.7	4
207	The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. European Journal of Cancer, 2015, 51, 2423-2433.	1.3	28
208	Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution. Gastric Cancer, 2015, 18, 346-353.	2.7	23
209	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)â€"Final overall and subgroup results.. Journal of Clinical Oncology, 2015, 33, 4003-4003.	0.8	11
210	A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY).. Journal of Clinical Oncology, 2015, 33, TPS4136-TPS4136.	0.8	7
211	An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID).. Journal of Clinical Oncology, 2015, 33, 110-110.	0.8	7
212	Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).. Journal of Clinical Oncology, 2015, 33, 167-167.	0.8	18
213	Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).. Journal of Clinical Oncology, 2015, 33, 2-2.	0.8	23
214	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 237-237.	0.8	5
215	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€"A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. Journal of Clinical Oncology, 2015, 33, 9-9.	0.8	7
216	A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.. Journal of Clinical Oncology, 2015, 33, TPS226-TPS226.	0.8	25

#	Article	IF	Citations
217	Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer (GC): Clinical implications for prognosis and peritoneal recurrence.. Journal of Clinical Oncology, 2015, 33, 23-23.	0.8	0
218	Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.. Journal of Clinical Oncology, 2015, 33, 175-175.	0.8	0
219	Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.. Journal of Clinical Oncology, 2015, 33, 4084-4084.	0.8	0
220	Phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin and bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis.. Journal of Clinical Oncology, 2015, 33, e15060-e15060.	0.8	0
221	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	0.8	0
222	A phase 1 trial of a potent and selective VEGF receptor inhibitor, apatinib, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2525-2525.	0.8	0
223	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. Journal of Clinical Oncology, 2015, 33, 11010-11010.	0.8	0
224	A randomized phase III study of adjuvant capecitabine vs observation in curatively resected stage IB (by) Tj ETQq0 0 0 rgBT /Overlock 10 TPS4137-TPS4137.	0.8	0
225	Phase I/II study of a combination of capecitabine, cisplatin, and intraperitonealdocetaxel (XP ID) in patients with advanced gastric cancer with peritoneal metastasis.. Journal of Clinical Oncology, 2015, 33, 4026-4026.	0.8	0
226	Phase II study of everolimus as a salvage treatment after failure of fluoropyrimidine and platinum in patients with metastatic gastric cancer positive for pS6Ser240/4 expression.. Journal of Clinical Oncology, 2015, 33, 4057-4057.	0.8	0
227	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 439-450.	4.2	21
228	Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. Annals of Oncology, 2014, 25, 2272-2277.	0.6	30
229	Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA - Journal of the American Medical Association, 2014, 312, 57.	3.8	515
230	A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 19-23.	0.6	7
231	A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/Tâ€Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. Oncologist, 2014, 19, 1129-1130.	1.9	16
232	A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Investigational New Drugs, 2014, 32, 355-361.	1.2	104
233	Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Investigational New Drugs, 2014, 32, 271-278.	1.2	25
234	Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). Cancer Chemotherapy and Pharmacology, 2014, 73, 139-149.	1.1	25

#	Article	IF	Citations
235	Quality of Life in the Trastuzumab for Gastric Cancer Trial. Oncologist, 2014, 19, 712-719.	1.9	50
236	The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. Annals of Surgical Oncology, 2014, 21, 4211-4217.	0.7	40
237	Prognostic significance of neuroendocrine components in gastric carcinomas. European Journal of Cancer, 2014, 50, 2802-2809.	1.3	52
238	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. Journal of Clinical Oncology, 2014, 32, 10549-10549.	0.8	1
239	Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2507-2507.	0.8	20
240	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, TPS4147-TPS4147.	0.8	3
241	EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. Journal of Clinical Oncology, 2014, 32, 172-172.	0.8	26
242	A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA).. Journal of Clinical Oncology, 2014, 32, 141-141.	0.8	0
243	Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.. Journal of Clinical Oncology, 2014, 32, 4028-4028.	0.8	0
244	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2574-2574.	0.8	0
245	Analysis of serum protein biomarkers and circulating tumor (ct) DNA for activity of dovitinib in patients (pts) with tyrosine kinase inhibitor (TKI)-refractory gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2014, 32, 10550-10550.	0.8	1
246	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.. Journal of Clinical Oncology, 2014, 32, 10544-10544.	0.8	0
247	Rectal gastrointestinal stromal tumor: clinical features, endoscopic findings and prognosis. Hepato-Gastroenterology, 2014, 61, 70-5.	0.5	2
248	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1271-1277.	1.8	66
249	A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1609-1617.	1.1	29
250	Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation. Cancer Chemotherapy and Pharmacology, 2013, 71, 43-51.	1.1	18
251	Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 1175-1182.	5.1	159
252	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	5.1	418

#	Article	IF	Citations
253	A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Investigational New Drugs, 2013, 31, 616-622.	1.2	20
254	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 295-302.	6.3	1,144
255	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 490-499.	5.1	740
256	The Effects of Surgical Cytoreduction Prior to Imatinib Therapy on the Prognosis of Patients with Advanced GIST. Annals of Surgical Oncology, 2013, 20, 4212-4218.	0.7	41
257	A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2013, 72, 815-823.	1.1	48
258	Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800Âmg/day in patients with advanced gastrointestinal stromal tumors. Investigational New Drugs, 2013, 31, 1367-1374.	1.2	23
259	Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. Radiology, 2013, 269, 603-611.	3.6	124
260	Serum <scp>CA</scp> 19â€9 as a prognostic factor in patients with metastatic gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 324-330.	0.7	28
261	Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). British Journal of Cancer, 2013, 108, 1245-1251.	2.9	50
262	Postoperative Nodal Status and Diffuse-type Histology Are Independent Prognostic Factors in Resectable Advanced Gastric Carcinomas After Preoperative Chemotherapy. American Journal of Surgical Pathology, 2013, 37, 1022-1029.	2.1	28
263	Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients. Journal of Korean Medical Science, 2013, 28, 1248.	1.1	9
264	Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2013, 31, 10501-10501.	0.8	8
265	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. Journal of Clinical Oncology, 2013, 31, 10503-10503.	0.8	26
266	Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.. Journal of Clinical Oncology, 2013, 31, 4021-4021.	0.8	24
267	Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).. Journal of Clinical Oncology, 2013, 31, TPS4150-TPS4150.	0.8	16
268	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)â€"A study by the Australasian Gastrointestinal Trials Group (AGITG).. Journal of Clinical Oncology, 2013, 31, TPS4157-TPS4157.	0.8	3
269	Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.. Journal of Clinical Oncology, 2013, 31, LBA10502-LBA10502.	0.8	5
270	Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2013, 31, 249-249.	0.8	43

#	Article	IF	Citations
271	Diagnosis and Treatment of Gastrointestinal Stromal Tumor. Korean Journal of Medicine, 2013, 85, 341.	0.1	4
272	A phase I dose-finding study of everolimus in combination with capecitabine and oxaliplatin (XELOX) as the first-line chemotherapy for patients with advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 86-86.	0.8	0
273	A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. Journal of Clinical Oncology, 2013, 31, 8521-8521.	0.8	0
274	Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.. Journal of Clinical Oncology, 2013, 31, LBA10502-LBA10502.	0.8	4
275	The role of surgical resection following imatinib treatment in patients with metastatic or recurrent GIST.. Journal of Clinical Oncology, 2013, 31, 10550-10550.	0.8	0
276	Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 2012, 6, 199-209.	1.4	69
277	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. Journal of Clinical Oncology, 2012, 30, 2119-2127.	0.8	434
278	Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2012, 18, 2090-2098.	3.2	167
279	Predictors of Recurrence After Resection of Small Gastric Gastrointestinal Stromal Tumors of 5 cm or Less. Journal of Clinical Gastroenterology, 2012, 46, 130-137.	1.1	16
280	An update of adjuvant treatments for localized advanced gastric cancer. Clinical Investigation, 2012, 2, 1101-1108.	0.0	3
281	Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Investigational New Drugs, 2012, 30, 2377-2383.	1.2	104
282	Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta OncolÃ³gica, 2012, 51, 528-536.	0.8	29
283	Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?. Human Pathology, 2012, 43, 413-422.	1.1	67
284	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e470-e481.	5.1	70
285	Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 523-529.	1.1	10
286	Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. Cancer Research and Treatment, 2012, 44, 85-96.	1.3	43
287	P-0303 Safety and Tolerability data from A Phase II Study of Auy922 Compared with Chemotherapy in Patients with Advanced Gastric Cancer. Annals of Oncology, 2012, 23, iv118.	0.6	1
288	Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Investigational New Drugs, 2012, 30, 1703-1708.	1.2	16

#	Article	IF	Citations
289	Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Investigational New Drugs, 2012, 30, 1607-1613.	1.2	24
290	Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. Gastric Cancer, 2012, 15, 305-312.	2.7	9
291	Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Investigational New Drugs, 2012, 30, 306-315.	1.2	51
292	Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Investigational New Drugs, 2012, 30, 819-827.	1.2	24
293	A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer.. Journal of Clinical Oncology, 2012, 30, 4082-4082.	0.8	10
294	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	0.8	2
295	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	0.8	11
296	Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, 5-5.	0.8	15
297	The role of surgical cytoreduction before imatinib therapy in patients with advanced GIST.. Journal of Clinical Oncology, 2012, 30, 10093-10093.	0.8	0
298	Pharmacokinetics of escalated dose of imatinib in patients with advanced gastrointestinal stromal tumors.. Journal of Clinical Oncology, 2012, 30, 10085-10085.	0.8	0
299	Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, e14617-e14617.	0.8	0
300	Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e31-e34.	1.8	0
301	Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Journal of Clinical Oncology, 2011, 29, 3968-3976.	0.8	1,003
302	Clinical impact of EUS-guided Trucut biopsy results on decision making for patients with gastric subepithelial tumors â‰¥2 cm in diameter. Gastrointestinal Endoscopy, 2011, 74, 1010-1018.	0.5	60
303	Clinico-hematologic Findings of Leukemic Bone Marrow Involvement in Korean Patients with Non-Hodgkin Lymphoma. Laboratory Medicine Online, 2011, 1, 81.	0.0	2
304	Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 145-154.	1.4	102
305	Association between deficient mismatch repair system and efficacy to irinotecanâ€containing chemotherapy in metastatic colon cancer. Cancer Science, 2011, 102, 1706-1711.	1.7	36
306	Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report. Journal of Medical Case Reports, 2011, 5, 504.	0.4	3

#	Article	IF	Citations
307	A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Investigational New Drugs, 2011, 29, 366-373.	1.2	73
308	A phase I study of S-1 treatment with a 3Âweek schedule in advanced biliary cancer patients with or without hepatic dysfunction. Investigational New Drugs, 2011, 29, 332-339.	1.2	2
309	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs, 2011, 29, 1449-1458.	1.2	179
310	Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 1435-1443.	1.1	27
311	Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemotherapy and Pharmacology, 2011, 68, 285-291.	1.1	18
312	A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemotherapy and Pharmacology, 2011, 68, 913-921.	1.1	69
313	A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 905-912.	1.1	1
314	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemotherapy and Pharmacology, 2011, 68, 1285-1290.	1.1	75
315	Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemotherapy and Pharmacology, 2011, 68, 1641-1642.	1.1	1
316	Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib. Clinical Cancer Research, 2011, 17, 4504-4512.	3.2	83
317	Results and implications of the Trastuzumab for Gastric Cancer (ToGA) trial. Clinical Investigation, 2011, 1, 87-95.	0.0	5
318	Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. Annals of Surgical Oncology, 2010, 17, 1024-1032.	0.7	53
319	Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 473-480.	1.1	23
320	Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 373-380.	1.1	12
321	Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. Journal of Korean Medical Science, 2010, 25, 1543.	1.1	25
322	Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation. Japanese Journal of Clinical Oncology, 2010, 40, 768-773.	0.6	74
323	Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib. Journal of Clinical Oncology, 2010, 28, 1554-1559.	0.8	88
324	Palliative Treatment of Malignant Gastric Outlet Obstructions with a Large-diameter Metallic Stent: Prospective Preliminary Study. Journal of Vascular and Interventional Radiology, 2010, 21, 1125-1128.	0.2	3

#	Article	IF	Citations
325	Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Oncology, 2010, 28, 3824-3829.	0.8	96
326	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, The, 2010, 376, 687-697.	6.3	5,899
327	Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors. Oncologist, 2009, 14, 540-547.	1.9	17
328	A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor. Oncology, 2009, 76, 326-332.	0.9	26
329	ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Review of Anticancer Therapy, 2009, 9, 1745-1751.	1.1	14
330	Reply to Are we representing the true population in oncology trials?. Annals of Oncology, 2009, 20, 2022-2023.	0.6	0
331	Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer. Gastric Cancer, 2009, 12, 38-42.	2.7	2
332	Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Medical Oncology, 2009, 26, 32-37.	1.2	47
333	Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology, 2009, 20, 666-673.	0.6	673
334	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2009, 10, 25-34.	5.1	5,104
335	Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 623-629.	1.1	65
336	A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemotherapy and Pharmacology, 2008, 61, 631-637.	1.1	65
337	Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 837-845.	1.1	29
338	A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2008, 63, 1-8.	1.1	28
339	Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). Journal of Surgical Oncology, 2008, 98, 27-33.	0.8	65
340	Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 811-816.	1.4	9
341	Prognostic Value of Tumor ¹⁸F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck. Journal of Nuclear Medicine, 2008, 49, 1783-1789.	2.8	68
342	Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor. Japanese Journal of Clinical Oncology, 2008, 39, 105-110.	0.6	21

#	Article	IF	Citations
343	Capecitabine in the treatment of advanced gastric cancer. Future Oncology, 2008, 4, 179-198.	1.1	11
344	Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 151-156.	0.6	29
345	Infarction and Perforation of the Small Intestine due to Tumor Emboli from Disseminated Rectal Cancer. Gut and Liver, 2008, 2, 130-132.	1.4	3
346	Combination Chemotherapy with Capecitabine (X) and Cisplatin (P) as First Line Treatment in Advanced Gastric Cancer: Experience of 223 Patients with Prognostic Factor Analysis. Japanese Journal of Clinical Oncology, 2007, 37, 30-37.	0.6	36
347	Extrapulmonary small cell carcinoma: Single center experience with 61 patients. Acta OncolÃ³gica, 2007, 46, 846-851.	0.8	81
348	Both-sided Intra-atrial Intracardiac Metastases as the Initial Presentation of Testicular Seminoma. Japanese Journal of Clinical Oncology, 2007, 37, 463-468.	0.6	5
349	Phase II Study of Biweekly Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Gastric Cancer: Korea Japan Collaborative Study Group Trial. Japanese Journal of Clinical Oncology, 2007, 37, 501-508.	0.6	7
350	Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis. Japanese Journal of Clinical Oncology, 2007, 37, 936-941.	0.6	41
351	A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 6182-6186.	3.2	18
352	Capecitabine in Advanced Gastric or Oesophagogastric Cancer. Drugs, 2007, 67, 611-612.	4.9	0
353	Metallic stent placement in the palliative treatment of malignant gastroduodenal obstructions: prospective evaluation of results and factors influencing outcome in 213 patients. Gastrointestinal Endoscopy, 2007, 66, 256-264.	0.5	185
354	Clinical Practice Guideline for Adequate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea. Journal of the Korean Medical Association, 2007, 50, 830.	0.1	5
355	Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. American Journal of Hematology, 2007, 82, 821-823.	2.0	78
356	Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2007, 61, 301-307.	1.1	88
357	A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia. Journal of Korean Medical Science, 2006, 21, 936.	1.1	8
358	Response to Imatinib in KIT- and PDGFRA-Wild Type Gastrointestinal Stromal Associated with Neurofibromatosis Type 1. Digestive Diseases and Sciences, 2006, 51, 1043-1046.	1.1	32
359	Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 2006, 99, 9-17.	1.1	135
360	Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response*. Japanese Journal of Clinical Oncology, 2006, 36, 704-711.	0.6	23

#	Article	IF	Citations
361	Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate. Japanese Journal of Clinical Oncology, 2006, 36, 17-24.	0.6	33
362	Neoadjuvant Imatinib in Locally Advanced G astrointestinal Stromal Tumors of the Stomach: Report of Three Cases. Cancer Research and Treatment, 2006, 38, 178.	1.3	7
363	Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. British Journal of Cancer, 2005, 92, 246-251.	2.9	34
364	Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast, 2005, 14, 304-309.	0.9	16
365	Three Cases Treated with High-dose Cytarabine and Etoposide followed by Autologous Stem Cell Transplantation for Relapsed Primary CNS Lymphoma. The Korean Journal of Hematology, 2005, 40, 172.	0.7	0
366	Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor. Journal of Korean Medical Science, 2005, 20, 512.	1.1	23
367	Phase II Study of Paclitaxel and Carboplatin in Advanced Gastric Cancer Previously Treated with 5-Fluorouracil and Platinum. Japanese Journal of Clinical Oncology, 2005, 35, 251-255.	0.6	16
368	A Randomised Crossover Study Comparing Ramosetron plus Dexamethasone with Ramosetron Alone in the Prevention of Cisplatin-Induced Emesis. Clinical Drug Investigation, 2005, 25, 191-197.	1.1	5
369	Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy. Cancer Research and Treatment, 2005, 37, 201.	1.3	5
370	BEAC or BEAM Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkinâ€™s Lymphoma Patients: Comparative Analysis on Efficacy and Toxicity.. Blood, 2005, 106, 5291-5291.	0.6	0
371	Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients. Journal of Korean Medical Science, 2004, 19, 397.	1.1	16
372	Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane. Journal of Korean Medical Science, 2004, 19, 547.	1.1	40
373	Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2004, 10, 3076-3081.	3.2	146
374	Leptomeningeal Carcinomatosis in Gastric Cancer. Journal of Neuro-Oncology, 2004, 66, 167-174.	1.4	84
375	Primary Malignant Lymphoma of the Breast: Clinicopathological Study of Nine Cases. Leukemia and Lymphoma, 2004, 45, 327-330.	0.6	30
376	Hand-Foot Syndrome in Patients Treated With Capecitabine-Containing Combination Chemotherapy. Journal of Clinical Pharmacology, 2004, 44, 1166-1172.	1.0	47
377	Clinicopathologic analysis of ocular adnexal lymphomas: Extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. American Journal of Hematology, 2003, 73, 87-96.	2.0	130
378	Title is missing!. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 98-102.	0.6	26

#	ARTICLE	IF	CITATIONS
379	Locally Advanced Acinar Cell Carcinoma of the Pancreas Successfully Treated by Capecitabine and Concurrent Radiotherapy: Report of Two Cases. Pancreas, 2003, 27, e18-e22.	0.5	33
380	The Prophylactic Use of Lamivudine Can Maintain Dose-Intensity of Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients with Non-Hodgkin's Lymphoma Who Receive Cytotoxic Chemotherapy. Journal of Korean Medical Science, 2003, 18, 849.	1.1	39
381	Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report. Journal of Clinical Oncology, 2002, 20, 1751-1758.	0.8	95
382	Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial. Japanese Journal of Clinical Oncology, 2002, 32, 248-254.	0.6	103
383	Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron. Journal of International Medical Research, 2002, 30, 220-229.	0.4	49
384	Polymerase chain reaction-based diagnosis of bone marrow involvement in 170 cases of non-Hodgkin lymphoma. Cancer, 2002, 94, 3073-3082.	2.0	20
385	Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2002, 50, 104-110.	1.1	28
386	Intensified induction followed by high-dose therapy with autologous peripheral blood stem cell support in poor-prognosis aggressive non-Hodgkin's lymphoma: results of a pilot study. Haematologica, 2002, 87, 555-7.	1.7	0
387	Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. Human Gene Therapy, 2001, 12, 671-684.	1.4	123
388	Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Letters, 2000, 159, 95-101.	3.2	66
389	TGF-?-induced cell-cycle arrest through the p21WAF1/CIP1-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells. , 1999, 83, 512-517.		35
390	Adjuvant (Cisplatin, Etoposide, and 5-Fluorouracil) Chemotherapy After Curative Resection of Gastric Adenocarcinomas Involving the Esophagogastric Junction. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 253-257.	0.6	2
391	Cellular Resistance to Adriamycin Conferred by Enhanced Rb Expression Is Associated with IncreasedMDR1Expression. Biochemical and Biophysical Research Communications, 1998, 249, 6-10.	1.0	2
392	Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant Î²-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization. Journal of Biological Chemistry, 1997, 272, 17118-17125.	1.6	604
393	Differential Depression of Lymphocyte Subsets According to Stage in Stomach Cancer. Japanese Journal of Clinical Oncology, 1991, 21, 87-93.	0.6	15